{"url":"https://nivawealth.com/firms/stonepine-capital-management-139891","iapdUrl":"https://adviserinfo.sec.gov/firm/summary/139891","regulatoryAum":181001870,"crd":"139891","history":[{"filedOn":"2021-03-30","regulatoryAum":246869329,"clients":1,"employees":5,"offices":2},{"filedOn":"2022-03-30","regulatoryAum":257734669,"clients":1,"employees":5,"offices":2},{"filedOn":"2023-06-08","regulatoryAum":271520031,"clients":1,"employees":5,"offices":2},{"filedOn":"2024-05-28","regulatoryAum":347828196,"clients":1,"employees":6,"offices":2},{"filedOn":"2026-06-26","regulatoryAum":181001870,"clients":1,"employees":4,"offices":2}],"secFileNumber":"801-136874","legalName":"Stonepine Capital Management, LLC","displayName":"Stonepine Capital Management","slug":"stonepine-capital-management-139891","website":"https://stonepinecap.com/","classification":{"segment":"private_funds","segmentLabel":"Private funds","type":"private_fund_manager","typeLabel":null,"feeDisclosure":"payment_only"},"founded":null,"organization":"Delaware limited liability company","fiscalYearEnd":"December","headquarters":{"street":"2900 NW Clearwater Drive, Suite 100-11","city":"Bend","state":"OR","stateName":"Oregon","country":"United States","postalCode":"97703"},"tradeNames":[],"registration":{"secApproved":"22 July 2026","noticeFilings":null,"latestNoticeFiling":null},"wealthAumPerClient":null,"staff":{"employees":4,"advisory":3,"brokerDealerReps":0,"insuranceAgents":0,"promoters":0},"aum":{"regulatory":181001870,"discretionary":181001870,"discretionaryAccounts":1,"nonDiscretionary":0,"nonDiscretionaryAccounts":0,"wrapProgram":null,"nonUsClientsPct":0,"nonAumClients":0},"clientTypes":[{"label":"Pooled investment vehicles","clients":1,"regulatoryAum":181001870}],"feePrograms":[],"brochureCoverage":{"scope":"known_documents","status":"not_processed","checkedAt":null,"documents":[]},"custodians":[],"custodyNote":"Stonepine Capital Management has custody of $181M in client assets for 1 client.","otherCustodians":[],"leadership":[{"name":"Lily Hou","title":"Chief Compliance Officer","crd":"6189894"},{"name":"Bryant Fong","title":"Member","crd":"6046549"},{"name":"Jeffrey Nunnenkamp","title":"Chief Operations Officer","crd":"4477816"},{"name":"Jon Plexico","title":"Managing Member","crd":"4608544"}],"ownership":[{"label":"Jon Plexico","detail":"Managing member in the 75% or more ownership band and a control person, since January 2006."},{"label":"Bryant Fong","detail":"Member in the 10% to 25% ownership band, since May 2024."}],"branchOffices":null,"filedOffices":{"otherThanPrincipal":1,"privateResidences":0},"listedOfficeAddresses":2,"foreignOffices":[],"officesByState":[{"state":"California","offices":1,"addresses":[{"street":"475 Gate Five Road","city":"Sausalito"}]},{"state":"Oregon","offices":1,"addresses":[{"street":"2900 NW Clearwater Drive, Suite 100-11","city":"Bend","headquarters":true}]}],"advFacts":{"source":{"file":"ia100226.zip","asOf":"2 October 2026"},"telephone":"541-647-5673","stateRegisteredReps":0,"otherAdviserReps":0,"compensation":["A percentage of assets under management","Performance-based fees"],"activities":["Portfolio management for pooled investment vehicles (other than investment companies)"],"financialPlanningClients":null,"assetMix":[],"privateFunds":1},"sources":{"adv1FilingDate":"26 June 2026","adv1Url":"https://reports.adviserinfo.sec.gov/reports/ADV/139891/PDF/139891.pdf","brochureDate":null,"brochureUrl":null,"iapdCompiledDate":null,"retrievedDate":"15 October 2026","retrievedOn":"2026-10-15","updatedOn":"2026-10-21","holdingsUpdatedOn":"2026-10-21","adv1Pages":{},"brochurePages":{}},"otherBusiness":[],"faq":[{"question":"How many clients does Stonepine Capital Management have?","answer":"Stonepine Capital Management has 1 client and manages $181 million for them, as of June 2026. They include 1 pooled investment vehicle.","source":"Form ADV Part 1A, Items 5.D and 5.F, filed 26 June 2026","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"What services does Stonepine Capital Management offer?","answer":"Stonepine Capital Management provides portfolio management for pooled vehicles.","source":"Form ADV Part 1A, Item 5.G, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"How many financial advisors does Stonepine Capital Management have?","answer":"Stonepine Capital Management has 0 investment adviser representatives registered with state securities authorities, out of 4 employees, and 3 perform investment advisory functions. None are registered representatives of a broker-dealer or licensed insurance agents.","source":"Form ADV Part 1A, Items 5.A and 5.B, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"Who owns Stonepine Capital Management?","answer":"Stonepine Capital Management’s direct owners are Jon Plexico (75% or more) and Bryant Fong (10% to 25%).","source":"Form ADV Part 1A, Schedules A and B, filed 26 June 2026","sourceRef":{"doc":"adv1","section":"scheduleA"}},{"question":"How does Stonepine Capital Management get paid?","answer":"Stonepine Capital Management is paid through a percentage of assets under management and performance-based fees. Its Form ADV lists no commissions among how it is paid.","source":"Form ADV Part 1A, Item 5.E, from the SEC's 2 October 2026 data file","sourceRef":{"doc":"adv1","section":"employees"}},{"question":"How do I contact Stonepine Capital Management?","answer":"Stonepine Capital Management’s main office is at 2900 NW Clearwater Drive, Suite 100-11, Bend, OR 97703. Its phone number is 541-647-5673. Its website is stonepinecap.com.","source":"Form ADV Part 1A, Item 1.F, filed 26 June 2026","sourceRef":{"doc":"adv1","section":"offices"}}],"holdings":{"url":"https://nivawealth.com/firms/stonepine-capital-management-139891/holdings","form":"13F-HR","periodOfReport":"2026-03-31","filedOn":"2026-05-14","filingIndexUrl":"https://www.sec.gov/Archives/edgar/data/1440771/000144077126000002/0001440771-26-000002-index.html","totalValue":249722452,"positionCount":83,"top10Share":0.7090046713140555,"top10":[{"issuer":"SPDR SERIES TRUST","titleOfClass":"STATE STREET SPD","cusip":"78464A870","value":51092000,"shares":400000,"shareType":"SH","putCall":"Call"},{"issuer":"SPDR SERIES TRUST","titleOfClass":"STATE STREET SPD","cusip":"78464A870","value":51092000,"shares":400000,"shareType":"SH","putCall":"Put"},{"issuer":"VERASTEM INC","titleOfClass":"COM NEW","cusip":"92337C203","value":17502190,"shares":3302300,"shareType":"SH"},{"issuer":"TENAX THERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"88032L605","value":15593448,"shares":975200,"shareType":"SH"},{"issuer":"ADMA BIOLOGICS INC","titleOfClass":"COM","cusip":"000899104","value":10361500,"shares":1150000,"shareType":"SH","putCall":"Call"},{"issuer":"EVOLUS INC","titleOfClass":"COM","cusip":"30052C107","value":7229864,"shares":1759091,"shareType":"SH"},{"issuer":"ADMA BIOLOGICS INC","titleOfClass":"COM","cusip":"000899104","value":6667400,"shares":740000,"shareType":"SH"},{"issuer":"CAMP4 THERAPEUTICS CORP","titleOfClass":"COM","cusip":"13463J101","value":6128233,"shares":1389622,"shareType":"SH"},{"issuer":"NEKTAR THERAPEUTICS","titleOfClass":"COM NEW","cusip":"640268306","value":6115750,"shares":85000,"shareType":"SH"},{"issuer":"TERNS PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"880881107","value":5272000,"shares":100000,"shareType":"SH","putCall":"Call"}],"positionsListed":83,"positions":[{"issuer":"SPDR SERIES TRUST","titleOfClass":"STATE STREET SPD","cusip":"78464A870","value":51092000,"shares":400000,"shareType":"SH","putCall":"Call"},{"issuer":"SPDR SERIES TRUST","titleOfClass":"STATE STREET SPD","cusip":"78464A870","value":51092000,"shares":400000,"shareType":"SH","putCall":"Put"},{"issuer":"VERASTEM INC","titleOfClass":"COM NEW","cusip":"92337C203","value":17502190,"shares":3302300,"shareType":"SH"},{"issuer":"TENAX THERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"88032L605","value":15593448,"shares":975200,"shareType":"SH"},{"issuer":"ADMA BIOLOGICS INC","titleOfClass":"COM","cusip":"000899104","value":10361500,"shares":1150000,"shareType":"SH","putCall":"Call"},{"issuer":"EVOLUS INC","titleOfClass":"COM","cusip":"30052C107","value":7229864,"shares":1759091,"shareType":"SH"},{"issuer":"ADMA BIOLOGICS INC","titleOfClass":"COM","cusip":"000899104","value":6667400,"shares":740000,"shareType":"SH"},{"issuer":"CAMP4 THERAPEUTICS CORP","titleOfClass":"COM","cusip":"13463J101","value":6128233,"shares":1389622,"shareType":"SH"},{"issuer":"NEKTAR THERAPEUTICS","titleOfClass":"COM NEW","cusip":"640268306","value":6115750,"shares":85000,"shareType":"SH"},{"issuer":"TERNS PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"880881107","value":5272000,"shares":100000,"shareType":"SH","putCall":"Call"},{"issuer":"ZEVRA THERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"488445206","value":4473600,"shares":480000,"shareType":"SH"},{"issuer":"CORBUS PHARMACEUTICALS HLDGS","titleOfClass":"COM NEW","cusip":"21833P301","value":3600708,"shares":383462,"shareType":"SH"},{"issuer":"ABEONA THERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"00289Y206","value":3344710,"shares":746587,"shareType":"SH"},{"issuer":"ESTABLISHMENT LABS HLDGS INC","titleOfClass":"COM","cusip":"G31249108","value":2839000,"shares":50000,"shareType":"SH","putCall":"Call"},{"issuer":"KAZIA THERAPEUTICS LTD","titleOfClass":"SPONSORED ADS","cusip":"48669G303","value":2568132,"shares":345179,"shareType":"SH"},{"issuer":"AN2 THERAPEUTICS INC","titleOfClass":"COM","cusip":"037326105","value":2441350,"shares":713845,"shareType":"SH"},{"issuer":"ALEXANDRIA REAL ESTATE EQ IN","titleOfClass":"COM","cusip":"015271109","value":2321000,"shares":50000,"shareType":"SH","putCall":"Call"},{"issuer":"ACADIA PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"004225108","value":2226000,"shares":100000,"shareType":"SH","putCall":"Call"},{"issuer":"SOL-GEL TECHNOLOGIES LTD","titleOfClass":"SHS NEW","cusip":"M8694L137","value":2200573,"shares":27778,"shareType":"SH"},{"issuer":"XOMA ROYALTY CORPORATION","titleOfClass":"COM NEW","cusip":"98419J206","value":2180215,"shares":69500,"shareType":"SH"},{"issuer":"AYTU BIOPHARMA INC","titleOfClass":"COM","cusip":"054754858","value":2162949,"shares":792289,"shareType":"SH"},{"issuer":"CURIS INC","titleOfClass":"COM","cusip":"231269309","value":2039462,"shares":3726406,"shareType":"SH"},{"issuer":"EVOLUS INC","titleOfClass":"COM","cusip":"30052C107","value":1726200,"shares":420000,"shareType":"SH","putCall":"Call"},{"issuer":"XERIS BIOPHARMA HOLDINGS INC","titleOfClass":"COM","cusip":"98422E103","value":1624000,"shares":280000,"shareType":"SH","putCall":"Call"},{"issuer":"TELA BIO INC","titleOfClass":"COM","cusip":"872381108","value":1622696,"shares":2617252,"shareType":"SH"},{"issuer":"INHIBIKASE THERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"45719W205","value":1608099,"shares":957202,"shareType":"SH"},{"issuer":"CRESCENT BIOPHARMA INC.","titleOfClass":"COM","cusip":"G2545C104","value":1561450,"shares":85000,"shareType":"SH"},{"issuer":"ADICET BIO INC","titleOfClass":"COM NEW","cusip":"007002207","value":1511514,"shares":221955,"shareType":"SH"},{"issuer":"X4 PHARMACEUTICALS INC","titleOfClass":"COM NEW","cusip":"98420X202","value":1384826,"shares":335309,"shareType":"SH"},{"issuer":"OKYO PHARMA LTD","titleOfClass":"SHS NEW","cusip":"G6724L116","value":1368500,"shares":850000,"shareType":"SH"},{"issuer":"SI BONE INC","titleOfClass":"COM","cusip":"825704109","value":1263000,"shares":100000,"shareType":"SH","putCall":"Call"},{"issuer":"MANNKIND CORP","titleOfClass":"COM NEW","cusip":"56400P706","value":1225000,"shares":500000,"shareType":"SH","putCall":"Call"},{"issuer":"HERON THERAPEUTICS INC","titleOfClass":"COM","cusip":"427746102","value":1121893,"shares":1402191,"shareType":"SH"},{"issuer":"PULMONX CORP","titleOfClass":"COM","cusip":"745848101","value":991092,"shares":768288,"shareType":"SH"},{"issuer":"IN8BIO INC","titleOfClass":"COM NEW","cusip":"45674E208","value":981850,"shares":663412,"shareType":"SH"},{"issuer":"NEUMORA THERAPEUTICS INC.","titleOfClass":"COM","cusip":"640979100","value":975000,"shares":500000,"shareType":"SH","putCall":"Call"},{"issuer":"SURROZEN INC","titleOfClass":"COM NEW","cusip":"86889P208","value":961436,"shares":33005,"shareType":"SH"},{"issuer":"CYTOMX THERAPEUTICS INC.","titleOfClass":"COM","cusip":"23284F105","value":940000,"shares":200000,"shareType":"SH"},{"issuer":"CYTOMX THERAPEUTICS INC.","titleOfClass":"COM","cusip":"23284F105","value":940000,"shares":200000,"shareType":"SH","putCall":"Call"},{"issuer":"DELCATH SYS INC","titleOfClass":"COM NEW","cusip":"24661P807","value":928000,"shares":100000,"shareType":"SH","putCall":"Call"},{"issuer":"ARDELYX INC","titleOfClass":"COM","cusip":"039697107","value":898500,"shares":150000,"shareType":"SH","putCall":"Call"},{"issuer":"PMV PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"69353Y103","value":878046,"shares":708102,"shareType":"SH"},{"issuer":"BIOAGE LABS INC","titleOfClass":"COM","cusip":"09077V100","value":874500,"shares":50000,"shareType":"SH"},{"issuer":"CONNECT BIOPHARMA HLDGS LTD","titleOfClass":"SHS","cusip":"G23549101","value":812200,"shares":310000,"shareType":"SH"},{"issuer":"HERON THERAPEUTICS INC","titleOfClass":"COM","cusip":"427746102","value":800100,"shares":1000000,"shareType":"SH","putCall":"Call"},{"issuer":"RADIOPHARM THERANOSTICS LTD","titleOfClass":"SPONSORED ADS","cusip":"75041J101","value":738977,"shares":51000000,"shareType":"SH"},{"issuer":"MAXCYTE INC","titleOfClass":"COM","cusip":"57777K106","value":705783,"shares":1004673,"shareType":"SH"},{"issuer":"CODEXIS INC","titleOfClass":"COM","cusip":"192005106","value":681330,"shares":417994,"shareType":"SH"},{"issuer":"BOUNDLESS BIO INC","titleOfClass":"COM","cusip":"10170A100","value":657450,"shares":597682,"shareType":"SH"},{"issuer":"CYBIN INC","titleOfClass":"COM NEW","cusip":"23256X407","value":643488,"shares":134060,"shareType":"SH"},{"issuer":"ZENTALIS PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"98943L107","value":629694,"shares":269100,"shareType":"SH"},{"issuer":"PASITHEA THERAPEUTICS CORP","titleOfClass":"COM NEW","cusip":"70261F202","value":616659,"shares":831301,"shareType":"SH"},{"issuer":"SATELLOS BIOSCIENCE INC","titleOfClass":"COM","cusip":"80401L803","value":563000,"shares":100000,"shareType":"SH"},{"issuer":"PHATHOM PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"71722W107","value":555611,"shares":50010,"shareType":"SH"},{"issuer":"ONKURE THERAPEUTICS INC","titleOfClass":"COM CL A","cusip":"68277Q105","value":548873,"shares":132578,"shareType":"SH"},{"issuer":"XILIO THERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"98422T209","value":539602,"shares":64162,"shareType":"SH"},{"issuer":"VERRICA PHARMACEUTICALS INC","titleOfClass":"COM SHS","cusip":"92511W207","value":527598,"shares":99735,"shareType":"SH"},{"issuer":"CANDEL THERAPEUTICS INC","titleOfClass":"COM","cusip":"137404109","value":502250,"shares":102500,"shareType":"SH"},{"issuer":"ABEONA THERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"00289Y206","value":448000,"shares":100000,"shareType":"SH","putCall":"Call"},{"issuer":"PRECISION OPTICS CORP INC MA","titleOfClass":"COM NEW","cusip":"740294400","value":439000,"shares":100000,"shareType":"SH"},{"issuer":"QUOIN PHARMACEUTICALS LTD","titleOfClass":"SPONSORED ADS","cusip":"74907L409","value":352836,"shares":53460,"shareType":"SH"},{"issuer":"ESTABLISHMENT LABS HLDGS INC","titleOfClass":"COM","cusip":"G31249108","value":340680,"shares":6000,"shareType":"SH"},{"issuer":"UPSTREAM BIO INC","titleOfClass":"COM","cusip":"91678A107","value":315000,"shares":35000,"shareType":"SH"},{"issuer":"OPUS GENETICS INC","titleOfClass":"COM","cusip":"67577R102","value":312530,"shares":68688,"shareType":"SH"},{"issuer":"ARVINAS INC","titleOfClass":"COM","cusip":"04335A105","value":291500,"shares":27500,"shareType":"SH"},{"issuer":"PLIANT THERAPEUTICS INC","titleOfClass":"COM","cusip":"729139105","value":283059,"shares":224650,"shareType":"SH"},{"issuer":"JANUX THERAPEUTICS INC","titleOfClass":"COM","cusip":"47103J105","value":278000,"shares":20000,"shareType":"SH"},{"issuer":"OMNIAB INC","titleOfClass":"COM","cusip":"68218J103","value":257551,"shares":164045,"shareType":"SH"},{"issuer":"XERIS BIOPHARMA HOLDINGS INC","titleOfClass":"COM","cusip":"98422E103","value":232174,"shares":40030,"shareType":"SH"},{"issuer":"COMPUGEN LTD","titleOfClass":"ORD","cusip":"M25722105","value":222159,"shares":104300,"shareType":"SH"},{"issuer":"NEUMORA THERAPEUTICS INC.","titleOfClass":"COM","cusip":"640979100","value":195000,"shares":100000,"shareType":"SH"},{"issuer":"SAB BIOTHERAPEUTICS INC","titleOfClass":"COM NEW","cusip":"78397T202","value":191500,"shares":50000,"shareType":"SH"},{"issuer":"SI BONE INC","titleOfClass":"COM","cusip":"825704109","value":188995,"shares":14964,"shareType":"SH"},{"issuer":"EDESA BIOTECH INC","titleOfClass":"COM NEW","cusip":"27966L306","value":156900,"shares":30000,"shareType":"SH"},{"issuer":"CNS PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"18978H508","value":145790,"shares":61000,"shareType":"SH"},{"issuer":"PROCESSA PHARMACEUTICALS INC","titleOfClass":"COM SHS","cusip":"74275C403","value":138875,"shares":55000,"shareType":"SH"},{"issuer":"CABALETTA BIO INC","titleOfClass":"COM","cusip":"12674W109","value":134500,"shares":50000,"shareType":"SH"},{"issuer":"KALARIS THERAPEUTICS INC","titleOfClass":"COM","cusip":"482929106","value":117708,"shares":20400,"shareType":"SH"},{"issuer":"ELEDON PHARMACEUTICALS INC","titleOfClass":"COM","cusip":"28617K101","value":107800,"shares":35000,"shareType":"SH"},{"issuer":"OVID THERAPEUTICS INC","titleOfClass":"COM","cusip":"690469101","value":88800,"shares":40000,"shareType":"SH"},{"issuer":"EVAXION AS","titleOfClass":"SPONSORED ADS","cusip":"29970R303","value":73332,"shares":19713,"shareType":"SH"},{"issuer":"MANNKIND CORP","titleOfClass":"COM NEW","cusip":"56400P706","value":39935,"shares":16300,"shareType":"SH"},{"issuer":"BIOATLA INC","titleOfClass":"COM","cusip":"09077B104","value":10527,"shares":65387,"shareType":"SH"}]},"notice":"Compiled from public SEC Form ADV filings on the dates in `sources`. Facts as filed; not a rating, ranking, or recommendation. Niva is not affiliated with this firm. Disciplinary history is deliberately not included here or on the page; the SEC publishes the complete record at the `iapdUrl` above."}